Is Axillary Lymph Node Dissection Needed? Clinicopathological Correlation in a Series of 224 Neoadjuvant Chemotherapy-Treated Node-Positive Breast Cancers
Authors:
- 10 November 2024
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 25 (2) , 172-179
Abstract
No abstract availableKeywords
Funding Information
- Brown University
This publication has 17 references indexed in Scilit:
- Abstract GS02-07: Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304Cancer Research, 2024
- Non-sentinel node metastasis prediction during surgery in breast cancer patients with one to three positive sentinel node(s) following neoadjuvant chemotherapyScientific Reports, 2023
- MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysisnpj Breast Cancer, 2022
- Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 studyBreast Cancer Research and Treatment, 2018
- Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2017
- Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIALRadiology, 2016
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort studyThe Lancet Oncology, 2013
- Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trialThe Lancet Oncology, 2010
- Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissectionJournal of Surgical Oncology, 2010